SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and sol...
multiple-myeloma-breakthrough
The future of CAR T-cell therapy: an analysis of its rapid growth and expansion.
Within the realm of contemporary medicine, CAR T-cell therapy emerges as an innovative and groundbreaking intervention...
multiple-myeloma-breakthrough
Introduction
Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal outcomes. A high-efficacy, safe CAR-T trea...
multiple-myeloma-breakthrough